Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Mycophenolate mofetil is a prescription antimetabolite immunosuppressant also marketed as CellCept. It is indicated to prevent organ rejection in adults and children age 3 months and older receiving allogeneic kidney, heart, or liver transplants. It is used with other immunosuppressive medicines and is available as capsules, tablets, oral suspension, and injectable formulations.
read more about mycophenolate mofetil ...Mycophenolate mofetil is converted to mycophenolic acid, which inhibits inosine monophosphate dehydrogenase. This blocks a pathway needed for guanosine nucleotide synthesis. B and T lymphocytes rely heavily on this pathway to multiply, so the medicine reduces immune activity that can contribute to transplanted organ rejection.
Mycophenolate mofetil is used with other immunosuppressants in adults and pediatric patients age 3 months and older after qualifying kidney, heart, or liver transplantation. Patients require close monitoring for infections, blood-cell abnormalities, and medication toxicity. Pregnancy planning and contraception counseling are particularly significant because exposure during pregnancy can cause miscarriage or congenital malformations.
Adults receiving a kidney transplant usually take 1 g by mouth twice daily. Adult heart and liver transplant recipients generally take 1.5 g orally twice daily. Pediatric dosing is based on body surface area and transplanted organ, commonly starting at 600 mg per square meter twice daily with indication-specific maximum doses. Capsules and tablets are swallowed intact. Mycophenolate mofetil must not be substituted directly with mycophenolic acid delayed-release products.
Mycophenolate mofetil carries boxed warnings for first-trimester pregnancy loss and congenital malformations, increased risk of lymphoma and other cancers, and serious or fatal infections. Other concerns include low blood-cell counts, gastrointestinal bleeding, severe diarrhea, and neurologic complications. Females of reproductive potential use acceptable contraception during treatment and for six weeks afterward. Sexually active males and their partners use effective contraception during treatment and for at least 90 days afterward.
It helps prevent rejection of transplanted kidneys, hearts, or livers when used with other immunosuppressive medicines.
The recommended oral dose for adult kidney transplant recipients is 1 g twice daily.
Yes. Current U.S. labeling includes eligible kidney, heart, and liver transplant recipients from age 3 months, with pediatric doses determined by body surface area.
Yes. Its boxed warnings concern fetal harm and pregnancy loss, malignancies, and serious infections.
CELLCEPT (mycophenolate mofetil) Prescribing Information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/50758s052lbl.pdf. Date Accessed October 16, 2026.
DailyMed - MYCOPHENOLATE MOFETIL capsule. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3eb584dc-f72d-4545-96fa-ab3d47be41ce. Date Accessed October 16, 2026.
Mycophenolate. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548945/. Date Accessed October 16, 2026.
Mycophenolate. MedlinePlus. https://medlineplus.gov/druginfo/meds/a601081.html. Date Accessed October 16, 2026.
Mycophenolate Mofetil. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/5281078. Date Accessed October 16, 2026.